Eagle Pharmaceuticals, Inc. (EGRX) financial statements (2021 and earlier)

Company profile

Business Address 50 TICE BOULEVARD, SUITE 315
WOODCLIFF LAKE, NJ 07677
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10390108202110117108
Cash and cash equivalents10390108202110117108
Receivables51574754484560
Inventory, net of allowances, customer advances and progress billings87887712
Inventory87887712
Prepaid expense0116574
Other current assets2411110
Other undisclosed current assets2634922
Total current assets:166164168276179180186
Noncurrent Assets
Property, plant and equipment2222222
Intangible assets, net (including goodwill)53535455555657
Goodwill40404040404040
Intangible assets, net (excluding goodwill)13141415161617
Deferred income tax assets15151514141414
Other noncurrent assets17141816453
Total noncurrent assets:87848886757776
TOTAL ASSETS:253248257362255257262
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities30383330343847
Accounts payable613141051117
Accrued liabilities24242020282729
Debt887116545
Total current liabilities:384640146394252
Noncurrent Liabilities
Long-term debt and lease obligation25272931343636
Long-term debt, excluding current maturities25272931343636
Liabilities, other than long-term debt4333332
Other liabilities4333332
Total noncurrent liabilities:29303234373937
Total liabilities:677573180758189
Stockholders' equity
Stockholders' equity attributable to parent186173184182179176172
Common stock0000000
Treasury stock, value(204)(200)(177)(173)(172)(169)(169)
Additional paid in capital305296291285279273267
Retained earnings84766970737174
Total stockholders' equity:186173184182179176172
TOTAL LIABILITIES AND EQUITY:253248257362255257262

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues50504246484157
Cost of revenue
(Cost of Goods and Services Sold)
(10)(9)(10)(5)(8)(12)(18)
Other undisclosed gross profit    (13)  
Gross profit:40413241272939
Operating expenses(30)(26)(28)(37)3(44)(47)
Other undisclosed operating income (loss)    (27)1218
Operating income (loss):1015443(2)9
Nonoperating income (expense)2(6)2(7)0(0)(0)
Investment income, nonoperating0000 11
Other nonoperating income (expense)2(6)2(7)   
Interest and debt expense(0)(0)(1)(1)(1)(1)(1)
Income (loss) from continuing operations before equity method investments, income taxes:1185(4)3(3)9
Other undisclosed income from continuing operations before income taxes0011111
Income (loss) from continuing operations before income taxes:1195(3)3(3)9
Income tax expense (benefit)(3)(2)(6)0(2)0(2)
Net income (loss) available to common stockholders, diluted:87(0)(3)1(2)7

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):87(0)(3)1(2)7
Comprehensive income (loss), net of tax, attributable to parent:87(0)(3)1(2)7

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: